MX2016009312A - Composiciones y metodos para el tratamiento de la neovascularizacion y/o fuga intraocular. - Google Patents

Composiciones y metodos para el tratamiento de la neovascularizacion y/o fuga intraocular.

Info

Publication number
MX2016009312A
MX2016009312A MX2016009312A MX2016009312A MX2016009312A MX 2016009312 A MX2016009312 A MX 2016009312A MX 2016009312 A MX2016009312 A MX 2016009312A MX 2016009312 A MX2016009312 A MX 2016009312A MX 2016009312 A MX2016009312 A MX 2016009312A
Authority
MX
Mexico
Prior art keywords
treatment
methods
compositions
leakage
intraocular neovascularization
Prior art date
Application number
MX2016009312A
Other languages
English (en)
Inventor
Horn Gerald
Original Assignee
Ontogenesis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ontogenesis Llc filed Critical Ontogenesis Llc
Publication of MX2016009312A publication Critical patent/MX2016009312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención provee composiciones y métodos para el tratamiento de la neovascularización y/o fuga intraocular, incluyendo la degeneración macular húmeda relacionada con la edad; las composiciones usan de preferencia inhibidores de tirosina cinasa con una IC50 para el VEGFR2 de 20 nanomolar o menos, y una IC50 para c-MET de 20 nanomolar o menos.
MX2016009312A 2014-01-16 2015-01-09 Composiciones y metodos para el tratamiento de la neovascularizacion y/o fuga intraocular. MX2016009312A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461928061P 2014-01-16 2014-01-16
US201461969861P 2014-03-25 2014-03-25
PCT/US2015/010867 WO2015108787A2 (en) 2014-01-16 2015-01-09 Compositions and methods for the treatment of intraocular neovascularization and/or leakage

Publications (1)

Publication Number Publication Date
MX2016009312A true MX2016009312A (es) 2017-01-06

Family

ID=53520420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009312A MX2016009312A (es) 2014-01-16 2015-01-09 Composiciones y metodos para el tratamiento de la neovascularizacion y/o fuga intraocular.

Country Status (7)

Country Link
US (1) US10010610B2 (es)
EP (1) EP3094284A4 (es)
JP (1) JP2017503028A (es)
KR (1) KR20160126983A (es)
CA (1) CA2936239A1 (es)
MX (1) MX2016009312A (es)
WO (1) WO2015108787A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101674622B1 (ko) 2016-07-07 2016-11-09 국민대학교산학협력단 세스퀴테르펜 유도체의 신규한 용도
BR112021003307A2 (pt) 2018-08-28 2021-05-11 Cloudbreak Therapeutics, Llc formulações de emulsões de inibidores de multiquinase
CN111920940B (zh) * 2020-09-16 2022-04-05 易舟(上海)生物医药有限公司 一种眼用制剂及其制备方法和应用
WO2021158968A1 (en) 2020-02-06 2021-08-12 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
EP4252725A3 (en) 2020-03-25 2023-11-22 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
EP4171507A1 (en) * 2020-06-30 2023-05-03 Oculis SA Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
CN112263582B (zh) * 2020-11-04 2022-03-15 温州医科大学 S100A8/A9蛋白抑制剂Tepotinib及其应用
CN116251186A (zh) * 2021-12-09 2023-06-13 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
US9328162B2 (en) * 2010-02-25 2016-05-03 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
JP2015508104A (ja) * 2012-02-22 2015-03-16 トラスティーズ オブ タフツ カレッジ 治療薬の眼への送達のための組成物および方法
US9539259B2 (en) * 2012-05-23 2017-01-10 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
KR20150083117A (ko) * 2012-11-08 2015-07-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
CN105188779B (zh) * 2013-01-24 2017-12-12 博士伦公司 天然蜡的聚(氮/胺)衍生物和眼用组合物
US20140378401A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations

Also Published As

Publication number Publication date
EP3094284A4 (en) 2017-12-13
CA2936239A1 (en) 2015-07-23
KR20160126983A (ko) 2016-11-02
EP3094284A2 (en) 2016-11-23
WO2015108787A2 (en) 2015-07-23
JP2017503028A (ja) 2017-01-26
US20150196649A1 (en) 2015-07-16
WO2015108787A3 (en) 2015-11-12
US10010610B2 (en) 2018-07-03

Similar Documents

Publication Publication Date Title
MX2016009312A (es) Composiciones y metodos para el tratamiento de la neovascularizacion y/o fuga intraocular.
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
GB2553252A8 (en) Compositions and methods for inhibiting factor D
MY192927A (en) Fused bicyclic compounds for the treatment of disease
RS59900B1 (sr) Jedinjenja i kompozicije za moduliranje aktivnosti egfr mutant kinaze
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
EP3174539A4 (en) Inhibitors of bruton's tyrosine kinase
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
MX2017000776A (es) Polipeptidos fhbp meningococicos modificados.
MY186271A (en) Ophthalmic compositions and methods of use therefor
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
EA201790967A1 (ru) Химерные антигенные рецепторы против cldn и способы их применения
HK1226065A1 (zh) 連接物關聯激酶1的抑制劑、包含其的組合物、及其使用方法
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2018004091A (es) Antagonistas de il-17c para el tratamiento y/o prevencion de dermatitis atopica.